CAPLIPOINT - Fundamental Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Fundamental Rating: 4.4

Caplin Point Laboratories (CAPLIPOINT) presents itself as a nimble, high-margin pharma player with lean financials and steady earnings growth. It’s not the splashiest name on the NSE, but its metrics tell a story worth tuning into.

💹 Core Financials Breakdown

EPS: ₹70.6 — robust earnings base given its ₹2,086 price.

ROE: 21.7% | ROCE: 25.8% — excellent profitability; efficient capital deployment.

PAT Qtr YoY Growth: 17.6% — consistent upward trend in quarterly profits.

Debt-to-Equity: 0.00 — completely debt-free, rare in pharma, highly favorable.

Dividend Yield: 0.24% — modest yield; firm prioritizes reinvestment over payouts.

📊 Valuation Signals

P/E: 29.6 vs Industry PE: 34.0 — slightly undervalued within its peer set.

P/B: ~5.56 — premium to book, expected for a high-margin pharma firm.

PEG Ratio: 1.38 — fair valuation considering growth; no alarm bells here.

Intrinsic Value Estimate: ₹2,200–₹2,350 — current price close to fair value.

🏥 Business Model & Competitive Edge

Segment: Niche formulations, mainly Latin America & emerging markets.

Strengths

Low working capital cycle and lean operations.

Strong presence in underpenetrated pharma markets.

Solid compliance history and R&D investments.

Concerns

Limited domestic visibility.

Currency and regulatory risks from overseas exposures.

📉 Technical Indicators

RSI: 52.6 — neutral momentum; not overbought or oversold.

MACD: +4.04 — bullish trend; rising strength.

Volume slightly below average — market may be in watch mode.

🎯 Suggested Entry Zone

₹1,950 – ₹2,050: Near DMA50 & DMA200 levels.

Long-term investors may track any dip toward ₹1,452 (52-week low) for deep entry.

🧭 Long-Term Holding Guidance

Great pick for low-debt, high-efficiency portfolio themes with a 3–5 year horizon

Plays well in defensive and healthcare allocations.

Potential upside from expanding formulation footprint and domestic market foray.

Not volatile, not flashy—just quietly compounding earnings.

If you’re building a pharma-focused basket, I can help compare it with names like Suven Pharma or Laurus Labs to add more dimension to your picks. Just say the word. 💊📈✨

Edit in a page